Inventiva : Présentation corporate Octobre 2022

Developing innovative therapies in

NASH

Corporate Presentation

October 2022

DISCLAIMER

This presentation contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this presentation are forward-looking statements. These statements include, but are not limited to, forecasts and estimates with respect to Inventiva's pre-clinical programs and clinical trials, including recruitment, screening and enrolment for those trials, including the LEGEND trial for the treatment of NAFLD, the NATiV3 Phase III clinical trial with lanifibranor in NASH, the investigator-initiated Phase II trial of lanifibranor in patients with NAFLD and T2D, and the expected Phase IIb clinical trial of cedirogant led by AbbVie, potential development of odiparcil including potential trial design and regulatory pathway, clinical trial data releases and publications, the information, insights and impacts that may be gathered from clinical trials, the potential therapeutic benefits of lanifibranor generally and in combination with empagliflozin, the potential therapeutic benefits of odiparcil, the design of trials and any potential amendments to trial design and the anticipated benefits related thereto, the Company's agreement with Sino Biopharm, including expectations with respect to enrollment of patients in Greater China in the NATiV3 trial, pipeline and preclinical and clinical development plans, milestone payments, royalties and product sales, potential proceeds under the Company's financing arrangements, future activities, expectations, plans, growth, business prospects, competitive advantages and opportunities, including pipeline product development of Inventiva and the sufficiency of Inventiva's cash resources and cash runway. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "would", "could", "might", "should", "plans", "designed", "hopefully", "target", "aim" and "continue" and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Future events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, that product candidates will receive the necessary regulatory approvals, or that any of the anticipated milestones by Inventiva or its partners will be reached on their expected timeline, or at all. Actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates, due to a number of factors, including that Inventiva is a clinical-stage company with no approved products and no historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has a limited operating history and has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates, preclinical trials or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's clinical trials may not support Inventiva's product candidate claims, Inventiva may encounter substantial delays in its clinical trials or Inventiva may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, enrolment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Inventiva's control, Inventiva's product candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competition and Inventiva's business, and preclinical trials and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by the current COVID-19 pandemic and geopolitical events, such as the conflict between Russia and Ukraine, related sanctions and related impacts and potential impacts on the initiation, enrolment and completion of Inventiva's clinical trials on anticipated timelines, and macroeconomic conditions, including global inflation and uncertain financial markets. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward- looking statements, forecasts and estimates only speak as of the date of this presentation. Readers are cautioned not to place undue reliance on any of these forward-looking statements.

Please refer to the Universal Registration Document for the year ended December 31, 2021 filed with the Autorité des Marchés Financiers on March 11, 2022, the Annual Report on Form 20-F for the year ended December 31, 2021 filed with the Securities and Exchange Commission on March 11, 2022 and the financial report for the first half of 2022 filed Securities and Exchange Commission for additional information in relation to such factors, risks and uncertainties.

All information in this presentation is as of the date of the release. Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. The information with respect to Sino Biopharm included in this presentation is based on [disclosures made by Sino Biopharm] and is not the responsibility of Inventiva.

Corporate Presentation | 2022		Non-confidential - Property of Inventiva │ 2

Key take-aways

A Phase III First-in Class & Best- in-Class NASH Drug

Lanifibranor: only pan-PPAR agonist in clinical development for NASH

Positive Phase IIb topline data with statistical significance on NASH resolution andone stage fibrosis reduction

Mechanism of action addressing all key features of NASH

Breakthrough Therapy Designation granted by FDA

Pivotal Phase III initiated in Q3 2021 with topline results expected H2 2025

Two Phase 2 trials ongoing with results expected in Q1 2023 and H2 2023

Licensing and commercialization in Greater China with Sino Biopharm one of the largest Chinese pharmaceutical groups

Corporate Presentation | 2022

A Phase IIb Clinical Stage Collaboration with AbbVie

Cedirogant/ABBV-157 Small

molecule RORγT Inverse Agonist

Potential to more effectively inhibit IL- 17 production than antagonist approaches

Promising activity in Phase I study in psoriasis patients

Phase IIb dose-ranging study initiated Q4 2021 and expected to end Q1 2023

Inventiva eligible to receive milestone payments and sales royalties

Strong R&D Capabilities and Cash Position

R&D capabilities including wholly- owned 'pharma scale' discovery facilities with a discovery engine focused on nuclear receptors, transcription factors and epigenetic targets

Clinical Ops team in place in Europe and the United States

Strong U.S. and European shareholder base and experienced senior management team

Cash position allowing a runway through Q4 2023, excluding the €25m second tranche of the bullet loan facility secured with the European Investment Bank

Non-confidential - Property of Inventiva │ 3

Management team with extensive global experience across all stages of drug development and commercialization

Frédéric Cren, MA/MBA, CEO and Co- Founder

• Wide expertise within the areas of R&D, marketing, strategy and commercial operations
• Held senior positions at Abbott, Fournier, Solvay Pharma and The Boston Consulting Group
• Former member of both Fournier and Solvay Pharma Executive Committees

Pierre Broqua, Ph.D., CSO and Co-Founder

• Successfully managed numerous research programs leading to the discovery, development and commercialization of innovative compounds, including lanifibranor and Degarelix/ Firmagon®
• Held several senior research positions at Fournier, Solvay Pharma and Abbott

Jean Volatier, MA, CFO

• Former Head of controlling at URGO & Financial Director International Operations of Fournier
• Held various positions as CFO and started his career with PwC in Paris and Philadelphia

Alice Roudot-Ketelers, PharmD, VP

Clinical Operations and Pharmaceutical

Development

• Previously in charge of all drug development programs and cross-functional teams in Chemistry, CMC, non-clinical and clinical development up to Phase III at one of the major biotech companies in the NASH field

Corporate Presentation | 2022

Michael Cooreman, MD, CMO

• Gastroenterologist-hepatologist
• Held global roles in several companies including Takeda Pharmaceuticals, Merck, Mitsubishi Tanabe, ImmusanT and Novartis
• U.S. based

David Nikodem, Ph.D., VP U.S. Operations

• Former buyside portfolio manager and analyst for +15 years in public equities and VC
• U.S. based

Non-confidential - Property of Inventiva │ 4

Oral small molecule-focused discovery engine targeting nuclear receptors, transcription factors and epigenetic modulation

Library of ~240,000 compounds of which

60% proprietary

Wholly-owned 129,000 square foot pharma-like

Expertise: nuclear receptors, transcription factors, epigenetic targets

R&D facilities

Highly experienced R&D team of ~80 people

Clinical and Medical team based in Europe and in the US

Power of discovery engine underpins deep pipeline of clinical and discovery stage assets

Corporate Presentation | 2022		Non-confidential - Property of Inventiva │ 5